Mai University on November 30 and December 1, 2000, and we present here our Meeting Report as one of the representative successful outcomes of projects from the Overseas Scientific Research Survey (Cancer Program).
Memorial lectures
The special session included three lectures in memory of Prof. Wada and the newly established Takeo Wada Award lecture for young Thai scientists, at the beginning of the Symposium. The three memorial lectures, by Prof. Wada's daughter Dr. Sato Honma, Dr. Kohzoh Imai and Dr. Maitree Suttajit, were a highlight of this symposium. Dr. Honma, Professor of the Physiology Department at Hokkaido University Graduate School of Medicine, studied medicine as her father had, but she then went into basic medical research, studying circadian rhythms. In her lecture she spoke on the roots of her father's motivation for his own international medical exchange program between Japan and more than 14 developing countries in East Europe, the Middle East and Asia as follows: after his graduation from the School of Medicine in 1940, he became a naval medical officer on the aircraft carrier "Hiryu" during the period from Pearl Harbor to Midway. Prof. Wada's experience during World War II and his feeling of responsibility as a survivor led him to help people in many countries by teaching medicine and introducing new medical technology. Chiang Mai was one of his favorite places. Dr. Apiwat's Award lecture, entitled "Molecular Mechanisms of Nasopharyngeal Carcinoma Development," was another highlight of the morning. He raised the question of why nasopharyngeal carcinoma (NPC) is found most frequently in Chinese individuals-especially in the southern part of China, while infection of Epstein-Barr virus (EBV) as an etiologic factor is distributed world-wide. Based on molecular studies with EBV, Dr. Apiwat reported many new findings: involvement of EBV in lymphoma in Thailand, detection of EBV DNA in serum of NPC patients and its clinical application as a promising tumor marker, and genetic alterations and loss of heterozygosity in NPC. All participants congratulated Prof. Apiwat as the first awardee, and his lecture demonstrated that he is a highly competent young scientist with a well-deserved international reputation. We also felt that Prof. Wada, looking down from heaven, smiled on Prof. Apiwat's superb presentation.
Cancer prevention
Participants were aware from the Abstract that the goal of the symposium was to disseminate news on advancements of cancer research in such areas as carcinogenesis, diagnosis, prevention and treatment. The Symposium provided an excellent opportunity to exchange knowledge and experience, and also to create friendships in an academic atmosphere. Sixteen oral presentations on three themescancer prevention, cancer treatment and molecular mechanisms of cancer-were given by scientists from 13 institutions (9 Japanese, 3 Thai, 2 US, 1 Czech Republic and 1 UK), along with 17 poster presentations. More than 200 people took part during the 2 days.
Among the most notable speakers was Dr. Floyd W. Dunn, Visiting Professor, Department of Biochemistry, Chiang Mai University. Dr. Dunn has created a long and valuable friendship with Thai scientists in Chiang Mai University, a friendship that goes back to Dr. Dunn's work as a member of the University of Illinois College of Medicine-Chiang Mai Project, 1965 -1968 . In his presentation, Dr. Dunn, as a Visiting Professor, strongly recommended introducing cancer prevention into medical education, based on his world-wide knowledge and extensive study on the latest cancer research. He noted that "putting cancer prevention into medical education" was accepted as a new project at Baylor College of Medicine in Houston last year.
Dr. Hisataka Moriwaki, First Department of Internal Medicine, Gifu University School of Medicine, clearly demonstrated that the development of second primary cancer after curative treatment for preceding hepatocellular carcinoma could be prevented by one year administration of a synthetic analog of vitamin A, acyclic retinoid, or 4,5-dehydro-geranylgeranoic acid, and that this sustained preventive activity provided a good prognosis for cancer patients five years after its administration. Dr. Moriwaki discussed the preventive mechanism using the concept of clonal deletion of premalignant and latent malignant cells. Since liver cancer is common in Asian countries, Thai scientists showed strong interest in the cancer preventive effects of the compound, acyclic retinoid.
Dr. Kei Nakachi, Saitama Cancer Center Research Institute, reported on the cancer preventive activity of green tea among breast cancer patients. Epidemiological studies with 472 breast cancer patients revealed that increased consumption of green tea was closely associated with decreased numbers of axillary lymph node metastases among premenopausal breast cancer patients in stage I and II, and with increased expression of progesterone receptor and estrogen receptor among postmenopausal ones, resulting in improvement of prognosis with decreased recurrence.
Dr. Masami Suganuma, Saitama Cancer Center Research Institute, revealed a new function of tumor necrosis factor-α (TNF-α) as an endogenous tumor promoter and a central mediator of chronic inflammatory diseases (although TNF-α was originally identified as an anticancer factor). It is increasingly clear that understanding the role of TNF-α in tumor promotion is essential in determining a new strategy of cancer prevention. Dr. Suganuma demonstrated that tumor promotion in TNF-α-deficient mice is refractory to the tumor promoters okadaic acid and 12-O-tetradecanoylphorbol-13-acetate (TPA), suggesting that TNF-α is the key cytokine in tumor promotion. She also presented various results showing that other inflammatory cytokines, such as interleukin (IL)-1 and IL-6, play a part in tumor promotion.
Dr. Naoko Sueoka, Saga Medical School, revealed a new preventive effect of green tea on life-style related diseases. This idea was the result of long-running experiments in tumor promotion which proved that TNF-α, an endogenous tumor promoter, is a central mediator in chronic inflammatory diseases (see the paragraph on Dr. Suganuma's remarks). Since green tea inhibits TNF-α expression in the cells and TNF-α release from the cells, it was thought that green tea might be a preventive agent for chronic inflammatory diseases. Experiments showed that drinking green tea inhibited expression of TNF-α and IL-6 in the lungs of TNF-α transgenic mice, and the results of a prospective cohort study in Saitama Prefecture, Japan, clearly demonstrated a decreased relative risk of death from cardiovascular disease and life-prolonging effects on cumulative survival among those drinking at least 10 cups per day.
Dr. Porntipa Picha, Research Division, National Cancer Institute, Bangkok, reported on utilization of Thai herbs in cancer prevention, treatment and palliative care. Using the cytotoxic activity of various cell lines, Dr. Porntipa found that curcusone A, curcusone C and curculathyrane B-all isolated from the roots of Jatropha curcas, a local tea (processed and non-processed)-along with extract of Ganoderma lucidum and royal jelly were possible anticancer agents. A well-known Thai folk remedy for cancer patients consists of ingredients from five species of plants and five species of animals, and, in collaboration with the National Cancer Institute in the United States, the cytotoxic activities of this remedy are now under investigation.
Dr. Hideki Arimochi, Department of Biochemistry, Tokushima University, reported the results of a collaboration with Thai scientists: a study with gut microflora found that a culture of Lactobacillus acidophilus and Clostridium perfringens inhibited the number of aberrant crypt foci (ACF) in rats; a cell suspension of a new Escherichia coli strain carrying a plasmid with lycopene biosynthetic genes led to a decrease in ACF formation, and a new Bacteroides uniformis strain carrying a plasmid with human lactoferrin gene showed similar inhibitory effects; and intestinal bacteria that were genetically modified to produce chemopreventive agents inhibited colon carcinogenesis in animal experiments.
Cancer therapy
This session included four presentations. Dr. Sumitra Thongprasert, Division of Medical Oncology, Chiang Mai University reported on the present status and treatment of lung cancer in Thailand, where lung cancer ranked among the first ten leading sites of cancer for both sexes in 1997. Unfortunately, most lung cancer patients are in the inoperable stage III or the metastatic stage IV, and in the hospital they are usually treated with paclitaxel and carboplatin. Based on reports that megestrol acetate stimulates appetite and body weight gain in cancer patients with cachexia, Dr. Sumitra administered it to 40 patients, along with paclitaxel and carboplatin. The addition of megestrol acetate to chemotherapy resulted in an increase of body weight and serum albumin, but the results were statistically not significant, although partial remission was found in 30.7% of patients. Thus, an early detection method for lung cancer is urgently needed (see Dr. E. Sueoka's presentation).
Dr. Suresh V. Ambudkar, Division of Basic Sciences, National Cancer Institute, USA, reported on the mechanism of action of the multidrug resistance-linked ATP binding cassette (ABC) transporters, which include P-glycoprotein (Pgp), a multidrug resistance-associated protein and a mitoxiantrone-resistance protein, all of which function as ATP-dependent efflux pumps. In his presentation, the drug-binding sites and ATP binding site of Pgp, along with the kinetics of ATP hydrolysis, were analyzed.
Dr. B. Rohova, Academy of Sciences of the Czech Republic, reported three results, as follows: 1. Polymerbound drugs (mitomycin C and doxorubicin)-non-targeted or targeted with monoclonal antibodies-do not induce expression of FasL on selected cancer cells, thus protecting effector cells of the immune system against Fas-counterattack; 2. Pre-treatment with polymer-bound doxorubicin not only protects, but also mobilizes the defense mechanisms of the tumor-bearing hosts; 3. Treatment with selected monoclonal antibody-targeted polymerbound doxorubicin causes a rapid and complete rejection of established tumors and generates prolonged systemic anti-tumor immunity.
Dr. Nisa Chawapun, Department of Radiology, Chiang Mai University, gave a comprehensive review on the role of p53 in human carcinogenesis and emphasized that p53 gene therapy can be integrated with existing therapies for better local tumor control.
Molecular mechanisms of cancer
Dr. Eisaburo Sueoka, Saga Medical School, spoke on the overexpression of heterogeneous nuclear ribonucleoprotein B1 (hnRNP B1) as a new diagnostic biomarker for human lung cancer. As Dr. Sumitra had previously indicated, early detection of lung cancer in humans is the most urgently needed step toward extending survival of patients. Dr. Sueoka reported that hnRNP B1 protein was strongly expressed in 100% of stage I lung cancer cases, and elevation of hnRNP B1 was further confirmed in both roentgenographically occult lung cancers and bronchial dysplasia. Anti-hnRNP B1 antibody was also useful for detection of squamous cell carcinomas of oral and esophageal tissues, and even in oral leukoplakia, suggesting that hnRNP B1 will be a useful diagnostic biomarker for the early stages of lung cancer and various squamous cell carcinomas in humans.
Dr. Yasuhito Yuasa, Department of Molecular Oncology, Tokyo Medical and Dental University, identified molecular risks of gastric cancer by analyzing the methylation status of hMLH1 and expression of developmentrelated genes. Methylation of the mismatch repair gene hMLH1 was observed in 9 of 100 gastric cancers, but it was not found in normal intestinal metaplastic tissues adjacent to cancers, indicating that this condition may be specific to gastric cancers. The expression of CDX2 gene appeared to decrease progressively with the transition from well to poorly differentiated cancer cell lines; the expression of GATA4 and GATA5 genes was undetectable in several cell lines. Dr. Yuasa concluded that these gene aberrations may be related to gastric cancer and may play a role as risk factors.
In Africa, higher aflatoxin-albumin adduct levels were observed in hepatitis B virus (HBV) infection compared with those in uninfected children. Dr. Christopher P. Wild, Epidemiology and Health Services Research, School of Medicine, University of Leeds, UK, observed that, in Gambia, the strongest determinants of aflatoxin-albumin adducts were season and place of residence rather than HBV status or interindividual variations in aflatoxin metabolizing enzymes. Furthermore, exposure to HBV and aflatoxins occurs early in life, with evidence of transplacental aflatoxin exposure in Gambian children. Reduction of aflatoxin exposure and introduction of HBV vaccination were discussed.
Dr. Kazuhiko Uchida, Institute of Basic Medical Sciences, University of Tsukuba, presented the results of joint work with Kohn Kaen University and National Cancer Institute, Bangkok. Comparative genomic hybridization with quantitative polymerase chain reaction was performed on fresh frozen tissue from over 50 gallbladder cancers and intrahepatic biliary cancers in order to identify abnormality patterns of genomic copy number and oncogenes and tumor suppressor genes involved in the development and progression of these cancers. In Thailand, most intrahepatic biliary cancers examined were liver fluke-infected cases with chronic inflammation. Recurrent chromosomal gains were more prominent in gallbladder cancer than were chromosomal losses. Dr. Uchida discussed the usefulness of genomic phenotyping for classification of cancer types.
